MAP Founder, Dr. Stephen Salloway, Co-Authors JAMA Editorial on Advances in Blood Tests for Alzheimer's Disease"
class="bg-img"
fetchpriority="high"
loading="eager"
decoding="async">
MAP Founder, Dr. Stephen Salloway, Co-Authors JAMA Editorial on Advances in Blood Tests for Alzheimer's Disease
MAP Founder Stephen Salloway, MD, MS co-authored a July 2024 editorial in The Journal of the American Medical Association (JAMA) about significant advancements in Alzheimer's disease (AD) blood tests. He was also featured in a JAMA podcast on the same topic.
Key findings noted in the editorial and podcast include the fact that blood tests, particularly the APS2 test, improved diagnostic accuracy in both primary and specialty care for individuals with cognitive impairment. These tests are crucial for early diagnosis, especially with new amyloid monoclonal antibody treatments now available.
In addition, midlife changes in blood biomarkers were identified as risk factors for late-life dementia. Current biomarkers are promising for population-level risk assessment but not yet suitable for individual risk prediction in midlife.
These advancements signify a transformative period in AD care, moving toward early diagnosis, mol ecular confirmation, and targeted treatments.
Disclaimer: The content in this blog is for informational and educational purposes only and should not serve as medical advice, consultation, or diagnosis. If you have a medical concern, please consult your healthcare provider or seek immediate medical treatment.
MAP Founder, Dr. Stephen Salloway, Co-Authors JAMA Editorial on Advances in Blood Tests for Alzheimer's Disease"
class="bg-img"
fetchpriority="high"
loading="eager"
decoding="async">
.jpg?width=240&height=273&name=Salloway_Stephen%20(1).jpg)